ArticleLast Updated September 20182 min read
featured image

Non-Steroidal Anti-Inflammatory Medication (Systemic Drug)

Prescriber Highlights

  • Prostaglandin E2 EP4-receptor antagonist (systemic drug), a new class of NSAID for treating osteoarthritis pain in dogs that does not inhibit cyclooxygenase (COX)

  • Potentially causes fewer severe adverse effects in dogs than other NSAIDs

  • GI effects (eg, vomiting, diarrhea) possible

Uses, Indications

  • Approved for control of pain and inflammation associated with osteoarthritis in dogs

Contraindications, Warnings

  • Contraindications

Patients with hypersensitivity to grapiprant or its components

  • Warnings

    • Grapiprant has not been evaluated in dogs younger than 9 months of age or weighing less than 8 lbs (3.6 kgs)

    • Safe use has not been established in dogs used for breeding or in pregnant or lactating dogs

Side Effects

  • GI distress (eg, vomiting; diarrhea; decreased appetite; mucoid, watery, or bloody stools)

  • Decreased serum albumin and total protein

Drug Interactions

  • Grapiprant is a substrate of P-glycoprotein transport, but no clinically relevant drug interactions have been identified

  • No inhibition of metabolic pathways mediated by cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4

  • Concurrent use with other anti-inflammatory drugs (eg, COX-inhibiting NSAIDs, corticosteroids) should be avoided

  • Washout period suggested when switching from corticosteroids or COX-inhibiting NSAIDs to grapiprant


  • Clinical efficacy, adverse events

  • Appetite

  • Emesis

  • Stool characteristics

Client Information

  • May be given with or without food; however, if vomiting occurs, give with food

  • Most common adverse effects include vomiting, diarrhea, and decreased appetite

Dosage Forms

  • Grapiprant flavored tablets: 20 mg, 60 mg, and 100 mg

Compiled and summarized from Plumb’s® Veterinary Drugs by Shannon Palermo, VMD